Quick Menu

Upcoming Journals

Microbiology Research Journal International

Microbiology Research Journal International, 2456-7043,Vol.: 22, Issue.: 4


Anti-Coccidiosis Potential of Autoclaveable Antimicrobial Peptides from Xenorhabdus budapestensis Resistant to Proteolytic (Pepsin, Trypsin) Digestion Based on In vitro Studies


András Fodor1*, László Makrai2, László Fodor2, István Venekei3, Ferenc Husvéth4, László Pál4, Andor Molnár4, Károly Dublecz4, Csaba Pintér5, Sándor Józsa5 and Michael G. Klein6

1Department of Genetics, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, Szeged, H-6726, Hungary.

2Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Budapest, Hungary.

3Department of Biochemistry, Eötvös Loránd University, Budapest H-1117, Hungary.

4Department of Animal Sciences and Animal Husbandry, Georgikon Faculty, University of Pannonia, Széchenyi Street, 11 Keszthely, H-8360 Hungary.

5Georgikon Faculty, University of Pannonia, Deák Ferenc utca, 16, Keszthely, H-8360, Hungary.

6Department of Entomology, The Ohio State University, 1680 Madison Ave., Wooster, OH-44691, USA.


Article Information
(1) Xing Li, Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine, USA.
(1) Luz del Carmen Camacho Castillo, Instituto Nacional de Pediatría, México.
(2) Nagaraja Suryadevara, MAHSA University, Malaysia.
Complete Peer review History: http://www.sciencedomain.org/review-history/22705




Aims: To elucidate the anticoccidial potential of antimicrobial peptides from Xenorhabdus budapestensis on both causative pathogens (prokaryotic Clostridium perfringens and eukaryotic Eimeria tenella).

Objectives: (1) To establish if the antimicrobial compounds of the cell-free culture media (CFCM) of the entomopathogenic symbiotic bacterium species, X. budapestensis DSM 16342 (EMA) and X. szentirmaii DSM 16338 (EMC) were active against 13 independent pathogenic isolates of Clostridium perfringens in vitro; (2) To create a sterile, autoclaved, bio-preparation called “XENOFOOD”, for future in vivo feeding studies, aimed at determining the efficacy, and side-effects, of EMA and EMC on C. perfringens in chickens.

Study Design: Clostridium perfringens samples (LH-1-LH24) were collected from chickens and turkeys, and were deposited in the frozen stock collection of Department of Microbiology and Infectious Diseases, Faculty of Veterinary Science, Szent István University, Budapest, Hungary, where the in vitro assays were carried out on 13 of these isolates.

Place and Duration of Study: Department of Microbiology and Infectious Diseases, Faculty of Veterinary Science, Szent István University, Budapest, Hungary between September 2013 and February 2014.

Methodology: Adaptation of our previously published in vitro bioassays for aerobic tests for the anaerobic bacteria Clostridium perfringens. When preparing “XENOFOOD” we benefitted from our experimental data about the heat tolerance and endurance to proteolytic enzymatic digestion of the studied antimicrobial peptides.

Results: The studied antimicrobial peptides were heat-stable, trypsin and pepsin resistant. All but one of 13 C. perfringens isolates was sensitive to EMA-CFCM. XENOFOOD (made here) is not toxic for chicken, (unpublished).

Conclusion: Since these cell-free cultures killed E. tenella cells, but were toxic to permanent chicken liver (LMH) cells, we need to run in vivo feeding tests to determine the gastrointestinal (ileac), anti-Clostridium and anti-Eimeria biological effects of the these heat, - and proteolysis tolerant antimicrobial peptides.


Keywords :

Clostridium perfringens; Xenorhabdus antimicrobial peptides; in-vitro bioassay; XENOFOOD.


Full Article - PDF    Page 1-17    Article Metrics


DOI : 10.9734/MRJI/2017/38516

Review History    Comments

Search this site

Advanced Search

Announcement & News

Nature (Impact Factor: 41.6) confirmed high standard of SDI journal and its editors

We are happy to inform that Nature (Impact Factor: 41.6) confirmed high standard of SDI journal and ...

ISI Thomson Reuters selected British Journal of Pharmaceutical Research for Emerging Sources Citation Index

We are delighted to inform that ISI Thomson Reuters selected British Journal of Pharmaceutical Resea...

SCOPUS selected Annual Research & Review in Biology (ARRB)

We are delighted to inform that famous indexing organization SCOPUS (from Elsevier) selected  A...

Index Copernicus Evaluation Result Released

We are delighted to inform that Index Copernicus (a leading indexing organization from Pol...

Journal Repository (JR): Permanent Digital Archiving of SDI journals

SDI is happy to announce that all our journals are now permanently archived in Journal Repository (J...

SDI journal got 35th ranking in Publons

We are delighted to announce (as of 04/01/2016) that British Journal of Medicine and Medical Re...

Growth of SDI and world publication market

As of 2014, total 25,064 journals are competing in World market of journal publication. In 2011, tot...

Science (IF: 31) report confirmed the high standard of SDI journal

As per a recent report (Link) of Science journal (present Impact factor 31), one of our journal (Bri...

SDI introduced Post-publication peer review by its comment section

SDI journals encourage Post-publication peer review by its comment section   Policy details a...

SDI promotes transparent Advanced OPEN peer review

We have migrated to transparent and toughest ‘Advanced OPEN peer review’ system (...


  • No Awards listed.

Browser Compatibility : Mozila firefox, Google Crome and IE 7 & above. Creative Commons License Terms & Condition   |   Privacy Policy   |   Join Us   |   Help   |   Contact Us
© Copyright 2010-2018, SCIENCEDOMAIN international. All rights reserved.